Study on Sacituzumab Govitecan and Zimberelimab with Radiation for Treating Metastatic Triple Negative Breast Cancer with Brain Metastases

Inclusion Criteria

• Must provide signed and dated consent to participate.
• Willing to follow all study procedures and available for the study duration.
• Age 18 or older.
• Diagnosed with triple negative breast cancer, meaning the cancer does not express certain hormone receptors.
• Cancer has spread to the brain, confirmed by MRI or surgery.
• Eligible for targeted brain radiation (SRS).
• Have measurable brain tumors that can be tracked by scans.
• Largest brain tumor must be 4 cm or smaller.
• In good general health with a performance status score of 0 to 2.
• If having symptoms, must have had surgery or be on a stable dose of steroids (8 mg/day or less).
• Previously treated with certain chemotherapy drugs.
• Can have had previous brain radiation if there is still active disease.
• Women of childbearing age must have a negative pregnancy test before each treatment.
• Men and women of childbearing potential must agree to use contraception.

Exclusion Criteria

• Have cancer spread to the lining of the brain and spinal cord.
• Pregnant or breastfeeding women.
• Have HIV with a detectable viral load.
• Have active or suspected autoimmune diseases, except for certain stable conditions.
• Have a history of lung inflammation requiring steroids or current lung disease.
• Have serious heart conditions, such as recent heart attack or severe heart failure.
• Require oxygen therapy.
• Have a serious infection needing antibiotics.
• Have active inflammatory bowel disease or recent bowel perforation.
• Have had other cancers, unless they are in remission and not being treated for at least 2 years.
• Have a medical condition that increases risk or affects study results.
• Have not recovered from major surgery or injury within 14 days before starting the study.
• Have had recent cancer treatments and not fully recovered.
• Have used investigational drugs recently.
• Have active hepatitis B or C with detectable viral loads.
• Have allergies to study drugs.
• Are prisoners or involuntarily incarcerated.
• Are detained for psychiatric or infectious disease treatment.